A phenothiazine derivative in the treatment of spasticity

Abstract

The efficacy of a selective fusimotor suppressant, the phenothiazine (±)-10-(3 dimethylamino 2 methylpropyl) 2 valeroylphenothiazine, has been assessed in a double blind cross over trial in 8 patients suffering from cerebral spasticity and 1 patient suffering from spinal spasticity. Dosage was 40 mg daily. Independent clinical and electromyographic methods of assessment were used. The active agent produced a small but significant reduction in spasticity, although this was of clinical value in only a few patients. There were few side effects. It is recommended that further studies using higher dosages be undertaken.